ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2774

Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort

Félicie Costantino 1, Philippe Aegerter 2, Anna Moltó 3, Georg Schett 4, Maxime Breban 5 and Maria-Antonietta D'Agostino6, 1UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, France, 2Public Health Department - GIRCI IdF - INSERM/Versailles-Saint Quentin University, France, Versailles, France, 3Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, 4Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, 5UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, 6UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne Billancourt, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Ankylosing spondylitis (AS), axial spondyloarthritis, severity and outcomes, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T094: Spondyloarthritis Including Psoriatic Arthritis – Clinical V: Axial Spondyloarthritis Clinical Studies (2774–2779)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: The course of axial spondyloarthritis (SpA) is heterogeneous and remains to be better defined. DESIR is a longitudinal French cohort of early undifferentiated axial SpA, allowing to define different disease courses. We recently performed a cluster analysis, based on baseline characteristics and identified 2 SpA clusters: one, characterized by an isolated axial disorder (A for axial), the other by additional high prevalence of peripheral manifestations (B for both) (Costantino et al. Arthritis Rheumatol, 2016). These two clusters may be linked to different levels of disease severity. The aim of the present study was to assess whether cluster-based SpA phenotypes identified at baseline are stable over time and might predict different severity disease outcomes at follow-up.

Methods: We analysed longitudinal data from the 535 patients fulfilling the ASAS classification criteria (either axial or peripheral criteria) and who completed all follow-up visits until year 5 (months 6, 12, 18, 24, 36, 48 and 60) out of the 679 patients in the DESIR cohort used to define clusters at baseline. We performed a linear mixed-effect analysis for quantitative variables and a generalized linear mixed-effect analysis for qualitative variables with cluster and follow-up visits as fixed effects and subjects as random effect. P-values were obtained by likelihood ratio tests of the full model with cluster against the model without cluster as fixed effects. To determine a way to predict a definite cluster in a given patient at baseline, a classification and regression tree (CART) analysis was performed. A 10-fold cross validation was used to estimate misclassification rates.

Results: Over the time, both clusters continued to show significant differences with respect to prevalence of peripheral involvement, higher disease activity, worse patient-reported outcome, higher frequency of conventional DMARDs and TNF inhibitor use in cluster B,  and higher prevalence of radiographic and MRI sacroiliitis at 2 and 5 years in cluster A (Table 1). CART analysis (Figure 1) shows that probability to maintain the same cluster over time is very high if a given patient belongs to a definite cluster-phenotype (A or B), with sensitivity of 98%, specificity of 87% and positive likelihood ratio of 7.62 at baseline (Table 2).

Conclusion: Cluster-based SpA phenotypes identify different severity outcomes at 5 years. We develop a decision tree for cluster determination, which shows accurate classification performance. This algorithm is easy to use (only three clinical parameters) and could help to identify patients at risk of poor outcome in early axial SpA.

Table 1. Results of the linear mixed effect and generalized linear mixed-effect analysis.

Table 2. Performance of the decision tree for cluster determination

Figure 1. Decision tree for cluster -number of patients in each cluster following by percentages are given in each case


Disclosure: F. Costantino, None; P. Aegerter, None; A. Moltó, None; G. Schett, AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, 8, AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, UCB, 5, BMS, Celgene, GSK, Lilly, Novartis, 2; M. Breban, None; M. D'Agostino, None.

To cite this abstract in AMA style:

Costantino F, Aegerter P, Moltó A, Schett G, Breban M, D'Agostino M. Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cluster-based-spondyloarthritis-phenotypes-defined-at-baseline-are-predictive-of-different-severity-outcomes-at-5-year-in-the-desir-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cluster-based-spondyloarthritis-phenotypes-defined-at-baseline-are-predictive-of-different-severity-outcomes-at-5-year-in-the-desir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology